A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies

@inproceedings{Yang2016A5C,
  title={A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies},
  author={Ting Yang and Qiaoxian Lin and Jinhua Ren and Ping Chen and Xiaohong Yuan and Xiaofeng Luo and Tingbo Liu and Jing Zheng and Zhihong Zheng and Xiaotian Zheng and Xinji Chen and Langhui Zhang and Hao Zheng and Zaisheng Chen and Xueling Hua and Shaohua Le and Jian Li and Zhizhe Chen and Jianda Hu},
  booktitle={Oncotarget},
  year={2016}
}
Haplo-HSCT has been used when HLA-matched siblings are not available. Conditioning regimens aim to reduce tumor burden prior to HSCT and provide sufficient immunoablation. We report the outcome of haplo-HSCT in 63 consecutive patients from 2/2013 to 12/2015 (19 females/44 males) with high-risk or relapsed/refractory hematological malignancies (n=29-AML; 8-sAML; 19-ALL; 5-advanced-MDS; 2-CML-BC). Median age was 20 years (range: 1.1-49). Twenty-one patients achieved remission prior to transplant… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES